Posted by Michael Wonder on 12 Mar 2019
Institute for Clinical and Economic Review publishes white paper on alternative models for pharmaceutical rebates
12 March 2019 - Paper explores how reforming or eliminating rebates may affect drug pricing, patient access, and incentives for future innovation; helps guide policy makers as they consider multiple options, including those recently proposed by the Trump Administration.
The Institute for Clinical and Economic Review, in collaboration with the Office of Health Economics, has released a new white paper: “Value, Access, and Incentives for Innovation: Policy Perspectives on Alternative Models for Pharmaceutical Rebates.” The paper outlines the potential advantages and disadvantages of three alternatives to the rebate model that currently drives pharmaceutical price negotiation in the US.
The white paper was developed following a December 2018 meeting of ICER’s membership program, during which leaders from the pharmaceutical and insurance industries convened to share their perspectives on how rebates grew increasingly important for their businesses, the unintended consequences they have had on drug affordability for certain patients, and possible paths forward.
